Boletín de AInvest
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
• Delcath Systems reports preliminary Q4 and FY25 financial results • Total Q4 revenue expected at $20.7 million, FY25 at $85.2 million • HEPZATO KIT Q4 revenue expected at $19 million, FY25 at $78.8 million • CHEMOSAT Q4 revenue expected at $1.7 million, FY25 at $6.4 million • Focus on primary and metastatic cancers of the liver treatment.
Titulares diarios de acciones y criptomonedas, gratis en tu bandeja de entrada
Comentarios
Aún no hay comentarios